<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00499655</url>
  </required_header>
  <id_info>
    <org_study_id>06254</org_study_id>
    <secondary_id>NCI-2010-00353</secondary_id>
    <secondary_id>CDR0000549751</secondary_id>
    <nct_id>NCT00499655</nct_id>
  </id_info>
  <brief_title>Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Randomized, Placebo-Controlled Phase II Clinical Trial of Combination Erlotinib (Tarceva) and Celecoxib (Celebrex) Versus Erlotinib (Tarceva)/Placebo in Advanced Non-Small Cell Lung Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>OSI Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Erlotinib hydrochloride and celecoxib may stop the growth of tumor cells by
      blocking some of the enzymes needed for cell growth. Celecoxib may also stop the growth of
      lung cancer by blocking blood flow to the tumor. Giving erlotinib hydrochloride together with
      celecoxib may kill more tumor cells.

      PURPOSE: This randomized phase II trial is studying how well giving erlotinib hydrochloride
      together with celecoxib works compared with erlotinib hydrochloride alone in treating
      patients with stage IIIB-IV non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Comparison of progression-free survival (PFS) in patients receiving erlotinib + celecoxib
      vs. erlotinib + placebo for advanced NSCLC.

      SECONDARY OBJECTIVES:

      I. Objective tumor response rate as defined by RECIST Criteria for subjects receiving
      erlotinib/celecoxib treatment arms.

      II. Categorize the change in e-cadherin expression from baseline to week 8 in a subset of
      subjects.

      III. Evaluation of overall survival (OS). IV. Measurement of COX-2, EGFR by
      immunohistochemistry and EGFR amplification by FISH, and EGFR mutation status to correlate
      with clinical response.

      V. Measurement of change in urinary PGE-M and correlation with response.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive oral erlotinib hydrochloride once daily and oral placebo twice daily
      on days 1-28.

      ARM II: Patients receive oral erlotinib hydrochloride once daily and oral celecoxib twice
      daily on days 1-28.

      In both arms, treatment repeats every 28 days for 12 courses in the absence of disease
      progression or unacceptable toxicity.

      After completion of study treatment, patients are followed periodically.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>Until disease progression, up to 5 years.</time_frame>
    <description>Estimated using the product-limit method of Kaplan and Meier.Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST), as a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Overall Response</measure>
    <time_frame>16 weeks post start of treatment</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival - Elevated PGEM</measure>
    <time_frame>Until disease progression, up to 5 years.</time_frame>
    <description>Estimated using the product-limit method of Kaplan and Meier.Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST), as a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival - EGRF</measure>
    <time_frame>Until disease progression, up to 5 years.</time_frame>
    <description>Estimated using the product-limit method of Kaplan and Meier.Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST), as a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival - Low PGEM</measure>
    <time_frame>Until disease progression, up to 5 years.</time_frame>
    <description>Estimated using the product-limit method of Kaplan and Meier.Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST), as a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Recurrent Non-small Cell Lung Cancer</condition>
  <condition>Stage IIIB Non-small Cell Lung Cancer</condition>
  <condition>Stage IV Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive oral erlotinib hydrochloride once daily and oral placebo twice daily on days 1-28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral erlotinib hydrochloride once daily and oral celecoxib twice daily on days 1-28.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>CP-358,774</other_name>
    <other_name>erlotinib</other_name>
    <other_name>OSI-774</other_name>
    <other_name>Tarceva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>Celebrex</other_name>
    <other_name>SC-58635</other_name>
    <other_name>YM 177</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>PLCB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>immunohistochemistry</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>fluorescence in situ hybridization</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>fluorescence in situ hybridization (FISH)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>mutation analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein expression analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion

          -  Pathologically proven NSCLC, stage IIIB (defined as: with pleural effusion or
             recurrence after mediastinal radiation and chemotherapy) or IV

          -  Available tumor tissue for mutation screening

          -  Measurable stage IIIb or IV disease by RECIST guidelines

          -  ECOG performance status of 0 or 1

          -  Progressive disease despite &gt;= 1 prior chemotherapy regimens as standard of care or
             subject's refusal or inability to receive standard chemotherapy

          -  Normal renal function (defined as serum creatinine =&lt; 2mg/dl)

          -  Normal liver function (defined as serum total bilirubin =&lt; 1.5, and serum
             transaminases =&lt; 2.5X the upper limits of normal [ULN]); if liver metastases are
             present, serum transaminases &gt; 5X the ULN

          -  No evidence of coagulopathy (defined as PT and/or PTT =&lt; 1.5X ULN or platelets &gt;=
             100,000)

          -  No evidence of leukopenia (defined as absolute neutrophil count &gt;= 1,500 mm^3)

          -  Negative pregnancy test prior to initiation of treatment and adequate contraception
             throughout treatment

        Exclusion

          -  Cytotoxic chemotherapy agents within 4 weeks of initiating treatment; all toxicities
             must be recovered to baseline or NCI CTCAE v3.0 Grade 1 from all acute effects of
             prior cancer treatment, except alopecia or any clinically insignificant effect, prior
             to study initiation

          -  Evidence of NYHA class III or greater cardiac disease, history of myocardial
             infarction, cerebral vascular accident, symptomatic ventricular arrhythmia, or
             symptomatic conduction abnormality

          -  Non-cytoxic therapy within 2 weeks of initiating treatment ; all toxicities must be
             recovered to baseline or NCI CTCAE v3.0 Grade 1 from all acute effects of prior cancer
             treatment, except alopecia or any clinically insignificant effect, prior to study
             initiation

          -  Prior radiotherapy to target lesions is not permitted unless completed more than 4
             weeks prior to treatment within the study and that there has been documented
             progression at these sites (Radiotherapy to non-target lesions is permitted within 2
             weeks of study entry provided all acute effects of the radiotherapy have resolved at
             least grade 1)

          -  Comorbid disease or a medical condition that would impair the ability of the subject
             to receive or comply with the study protocol

          -  Prior malignancy within the last 3 years with the exception of non-melanoma skin
             cancer or cervical cancer in situ

          -  Hypersensitivity of erlotinib or celecoxib or to any of the excipients of these
             products

          -  Hypersensitivity to sulfonamides, aspirin or other NSAIDS

          -  Prior history of EGFR inhibitor for the treatment of cancer

          -  Previous history of gastrointestinal ulceration, bleeding or perforation

          -  Concurrent use of COX-2 inhibitors or other NSAIDS (For subjects on NSAIDS prior to
             study initiation, cessation of the drug for 72 hours prior to study entry is required)

          -  Chronic or concurrent use of steroids (topical steroids are acceptable if medically
             indicated)

          -  Subjects who require treatment with fluconazole or lithium

          -  Any evidence of clinically active interstitial lung disease (patients with chronic
             stable radiographic changes who are asymptomatic need not be excluded)

          -  Renal insufficiency (defined as serum creatinine &gt; 2 mg/dl)

          -  Liver insufficiency (defined as serum total bilirubin &gt; 1.5, or serum transaminases &gt;
             2.5C the upper limits of normal [ULN]); if liver metastases are present, serum
             transaminases &gt; 5X the ULN

          -  Coagulopathy (defined as PT and/or PTT &gt; 1.5X ULN or platelets &lt; 100,000)

          -  Leukopenia (defined as absolute neutrophil count &lt; 1,500/mm^3)

          -  Pregnancy or inadequate contraception

          -  Lactating females

          -  Active CNS metastasis (stable, treated CNS metastasis acceptable)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Reckamp</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Pasadena Cancer Center</name>
      <address>
        <city>South Pasadena</city>
        <state>California</state>
        <zip>91030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2007</study_first_submitted>
  <study_first_submitted_qc>July 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2007</study_first_posted>
  <results_first_submitted>January 6, 2017</results_first_submitted>
  <results_first_submitted_qc>January 6, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 1, 2017</results_first_posted>
  <last_update_submitted>February 28, 2017</last_update_submitted>
  <last_update_submitted_qc>February 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Erlotinib\Placebo</title>
          <description>Patients receive 150 mg of oral erlotinib hydrochloride once daily and oral placebo twice daily on days 1-28.
erlotinib hydrochloride: Given orally
placebo: Given orally
laboratory biomarker analysis: Correlative studies
immunohistochemistry staining method: Correlative studies
fluorescence in situ hybridization: Correlative studies
mutation analysis: Correlative studies
protein expression analysis: Correlative studies
gene expression analysis: Correlative studies</description>
        </group>
        <group group_id="P2">
          <title>Erlotinib\Celecoxib</title>
          <description>Patients receive 150 mg of oral erlotinib hydrochloride once daily and 600 mg of oral celecoxib twice daily on days 1-28.
erlotinib hydrochloride: Given orally
celecoxib: Given orally
laboratory biomarker analysis: Correlative studies
immunohistochemistry staining method: Correlative studies
fluorescence in situ hybridization: Correlative studies
mutation analysis: Correlative studies
protein expression analysis: Correlative studies
gene expression analysis: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Erlotinib\Placebo</title>
          <description>Patients receive 150 mg of oral erlotinib hydrochloride once daily and oral placebo twice daily on days 1-28.
erlotinib hydrochloride: Given orally
placebo: Given orally
laboratory biomarker analysis: Correlative studies
immunohistochemistry staining method: Correlative studies
fluorescence in situ hybridization: Correlative studies
mutation analysis: Correlative studies
protein expression analysis: Correlative studies
gene expression analysis: Correlative studies</description>
        </group>
        <group group_id="B2">
          <title>Erlotinib\Celecoxib</title>
          <description>Patients receive 150 mg of oral erlotinib hydrochloride once daily and 600 mg of oral celecoxib twice daily on days 1-28.
erlotinib hydrochloride: Given orally
celecoxib: Given orally
laboratory biomarker analysis: Correlative studies
immunohistochemistry staining method: Correlative studies
fluorescence in situ hybridization: Correlative studies
mutation analysis: Correlative studies
protein expression analysis: Correlative studies
gene expression analysis: Correlative studies</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="53"/>
            <count group_id="B2" value="54"/>
            <count group_id="B3" value="107"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" lower_limit="30" upper_limit="80"/>
                    <measurement group_id="B2" value="63.5" lower_limit="41" upper_limit="80"/>
                    <measurement group_id="B3" value="64" lower_limit="30" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival</title>
        <description>Estimated using the product-limit method of Kaplan and Meier.Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST), as a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions.</description>
        <time_frame>Until disease progression, up to 5 years.</time_frame>
        <population>All patients receiving treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Erlotinib\Placebo</title>
            <description>Patients receive 150 mg of oral erlotinib hydrochloride once daily and oral placebo twice daily on days 1-28.
erlotinib hydrochloride: Given orally
placebo: Given orally
laboratory biomarker analysis: Correlative studies
immunohistochemistry staining method: Correlative studies
fluorescence in situ hybridization: Correlative studies
mutation analysis: Correlative studies
protein expression analysis: Correlative studies
gene expression analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Erlotinib\Celecoxib</title>
            <description>Patients receive 150 mg of oral erlotinib hydrochloride once daily and 600 mg of oral celecoxib twice daily on days 1-28.
erlotinib hydrochloride: Given orally
celecoxib: Given orally
laboratory biomarker analysis: Correlative studies
immunohistochemistry staining method: Correlative studies
fluorescence in situ hybridization: Correlative studies
mutation analysis: Correlative studies
protein expression analysis: Correlative studies
gene expression analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>Estimated using the product-limit method of Kaplan and Meier.Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST), as a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions.</description>
          <population>All patients receiving treatment.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="1.8" upper_limit="5.5"/>
                    <measurement group_id="O2" value="5.4" lower_limit="2" upper_limit="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Overall Response</title>
        <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR</description>
        <time_frame>16 weeks post start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Erlotinib\Placebo</title>
            <description>Patients receive 150 mg of oral erlotinib hydrochloride once daily and oral placebo twice daily on days 1-28.
erlotinib hydrochloride: Given orally
placebo: Given orally
laboratory biomarker analysis: Correlative studies
immunohistochemistry staining method: Correlative studies
fluorescence in situ hybridization: Correlative studies
mutation analysis: Correlative studies
protein expression analysis: Correlative studies
gene expression analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Erlotinib\Celecoxib</title>
            <description>Patients receive 150 mg of oral erlotinib hydrochloride once daily and 600 mg of oral celecoxib twice daily on days 1-28.
erlotinib hydrochloride: Given orally
celecoxib: Given orally
laboratory biomarker analysis: Correlative studies
immunohistochemistry staining method: Correlative studies
fluorescence in situ hybridization: Correlative studies
mutation analysis: Correlative studies
protein expression analysis: Correlative studies
gene expression analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Overall Response</title>
          <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival - Elevated PGEM</title>
        <description>Estimated using the product-limit method of Kaplan and Meier.Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST), as a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions.</description>
        <time_frame>Until disease progression, up to 5 years.</time_frame>
        <population>Analysis on a subset of patients with elevated baseline urinary prostaglandin E metabolite (PGEM).</population>
        <group_list>
          <group group_id="O1">
            <title>Erlotinib\Placebo</title>
            <description>Patients receive 150 mg of oral erlotinib hydrochloride once daily and oral placebo twice daily on days 1-28.
erlotinib hydrochloride: Given orally
placebo: Given orally
laboratory biomarker analysis: Correlative studies
immunohistochemistry staining method: Correlative studies
fluorescence in situ hybridization: Correlative studies
mutation analysis: Correlative studies
protein expression analysis: Correlative studies
gene expression analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Erlotinib\Celecoxib</title>
            <description>Patients receive 150 mg of oral erlotinib hydrochloride once daily and 600 mg of oral celecoxib twice daily on days 1-28.
erlotinib hydrochloride: Given orally
celecoxib: Given orally
laboratory biomarker analysis: Correlative studies
immunohistochemistry staining method: Correlative studies
fluorescence in situ hybridization: Correlative studies
mutation analysis: Correlative studies
protein expression analysis: Correlative studies
gene expression analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival - Elevated PGEM</title>
          <description>Estimated using the product-limit method of Kaplan and Meier.Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST), as a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions.</description>
          <population>Analysis on a subset of patients with elevated baseline urinary prostaglandin E metabolite (PGEM).</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="1.8" upper_limit="5.5"/>
                    <measurement group_id="O2" value="5.4" lower_limit="1.8" upper_limit="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival - EGRF</title>
        <description>Estimated using the product-limit method of Kaplan and Meier.Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST), as a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions.</description>
        <time_frame>Until disease progression, up to 5 years.</time_frame>
        <population>Analysis on a subset of patients with wild-type epidermal growth factor receptor (EGFR),</population>
        <group_list>
          <group group_id="O1">
            <title>Erlotinib\Placebo</title>
            <description>Patients receive 150 mg of oral erlotinib hydrochloride once daily and oral placebo twice daily on days 1-28.
erlotinib hydrochloride: Given orally
placebo: Given orally
laboratory biomarker analysis: Correlative studies
immunohistochemistry staining method: Correlative studies
fluorescence in situ hybridization: Correlative studies
mutation analysis: Correlative studies
protein expression analysis: Correlative studies
gene expression analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Erlotinib\Celecoxib</title>
            <description>Patients receive 150 mg of oral erlotinib hydrochloride once daily and 600 mg of oral celecoxib twice daily on days 1-28.
erlotinib hydrochloride: Given orally
celecoxib: Given orally
laboratory biomarker analysis: Correlative studies
immunohistochemistry staining method: Correlative studies
fluorescence in situ hybridization: Correlative studies
mutation analysis: Correlative studies
protein expression analysis: Correlative studies
gene expression analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival - EGRF</title>
          <description>Estimated using the product-limit method of Kaplan and Meier.Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST), as a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions.</description>
          <population>Analysis on a subset of patients with wild-type epidermal growth factor receptor (EGFR),</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="1.7" upper_limit="3.5"/>
                    <measurement group_id="O2" value="3.2" lower_limit="1.7" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival - Low PGEM</title>
        <description>Estimated using the product-limit method of Kaplan and Meier.Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST), as a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions.</description>
        <time_frame>Until disease progression, up to 5 years.</time_frame>
        <population>Analysis on a subset of patients with low baseline urinary prostaglandin E metabolite (PGEM).</population>
        <group_list>
          <group group_id="O1">
            <title>Erlotinib\Placebo</title>
            <description>Patients receive 150 mg of oral erlotinib hydrochloride once daily and oral placebo twice daily on days 1-28.
erlotinib hydrochloride: Given orally
placebo: Given orally
laboratory biomarker analysis: Correlative studies
immunohistochemistry staining method: Correlative studies
fluorescence in situ hybridization: Correlative studies
mutation analysis: Correlative studies
protein expression analysis: Correlative studies
gene expression analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Erlotinib\Celecoxib</title>
            <description>Patients receive 150 mg oforal erlotinib hydrochloride once daily and 600 mg of oral celecoxib twice daily on days 1-28.
erlotinib hydrochloride: Given orally
celecoxib: Given orally
laboratory biomarker analysis: Correlative studies
immunohistochemistry staining method: Correlative studies
fluorescence in situ hybridization: Correlative studies
mutation analysis: Correlative studies
protein expression analysis: Correlative studies
gene expression analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival - Low PGEM</title>
          <description>Estimated using the product-limit method of Kaplan and Meier.Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST), as a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions.</description>
          <population>Analysis on a subset of patients with low baseline urinary prostaglandin E metabolite (PGEM).</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="1.7" upper_limit="7.2"/>
                    <measurement group_id="O2" value="6.8" lower_limit="1.7" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events occurred over a period of 6 years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Erlotinib\Placebo</title>
          <description>Patients receive 150 mg of oral erlotinib hydrochloride once daily and oral placebo twice daily on days 1-28.
erlotinib hydrochloride: Given orally
placebo: Given orally
laboratory biomarker analysis: Correlative studies
immunohistochemistry staining method: Correlative studies
fluorescence in situ hybridization: Correlative studies
mutation analysis: Correlative studies
protein expression analysis: Correlative studies
gene expression analysis: Correlative studies</description>
        </group>
        <group group_id="E2">
          <title>Erlotinib\Celecoxib</title>
          <description>Patients receive 150 mg of oral erlotinib hydrochloride once daily and 600 mg of oral celecoxib twice daily on days 1-28.
erlotinib hydrochloride: Given orally
celecoxib: Given orally
laboratory biomarker analysis: Correlative studies
immunohistochemistry staining method: Correlative studies
fluorescence in situ hybridization: Correlative studies
mutation analysis: Correlative studies
protein expression analysis: Correlative studies
gene expression analysis: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE v3.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>cerebrovascular ischemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>cardiac ischemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE v3.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="53"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="40" subjects_affected="40" subjects_at_risk="53"/>
                <counts group_id="E2" events="38" subjects_affected="38" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="53"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="53"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="53"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="53"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="53"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated AST</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="53"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="53"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Elevated creatinine</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="53"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Elevated Alk Phos</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="53"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Elevated bilirubin</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="53"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="53"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="42" subjects_affected="42" subjects_at_risk="53"/>
                <counts group_id="E2" events="43" subjects_affected="43" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="40" subjects_affected="40" subjects_at_risk="53"/>
                <counts group_id="E2" events="36" subjects_affected="36" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Karen L. Reckamp, M.D.</name_or_title>
      <organization>City of Hope</organization>
      <phone>(626) 256-4673</phone>
      <email>kreckamp@coh.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

